Cannabinoids, along with having been scientifically proven to have a promising effect for autoimmmune diseases such as; arthritis, parkinsons and multiple sclerosis, also have an anti-inflammatory effect inside our body which is responsible for playing an active role in alleviating symptoms of head injuries and stroke. Investigators of this topic have used animal models to experiment further. Due to the positive results they have been noting, we can now research an important link between the immune system and cannabinoids.
This paper will look at the role of cannabinoids in the immune system and how they can be beneficial to immune system diseases.
Here is the full scientific article if you wish to download it.
Results on the effects of cannabinoid on immune system working serve not only to know how the endocannabinoid system changes immune phenomena related to infection or inflammation, but also to find therapeutic target sites for immune conditions. Cannabinoids can alter immune reactions in the periphery but also in the brain, influence T cell subset balance and cytokine expression and have apart to play in the balance between neuroinflammation and neurodegeneration. Immune cells can make endocannabinoids and also be influenced by cannabinoids. Cannabinoid receptors display separate expression on immune cells that depends on the triggering situation and stimuli.
The difficult nature of the interaction between cannabinoids and cannabinoid receptors gave the requirement to refine the basic conceptual profile of agonists and gave possible negative impacts in knowing the relationship in pathological conditions. The immune influence of cannabinoids is not fully elucidated.
However, parts of their immunomodulatory impacts give a good basis for a context-dependent targeted therapeutic method, thus leading to the potential application of cannabinoids in the treatment of inflammatory syndromes.
The immune impacts of cannabinoids and endocannabinoid system give promising therapeutic implications in a number of conditions. Multiple sclerosis: Used for symptom mediation such as muscle spasticity and pain in MS patients, cannabinoid agonists can give both immunomodulatory and neuroprotective properties.
In research models, immunomodulation was related with reduced myelin-specific T cell responses and decreased clinical disease. This implies indirect actions by CB1 nerve transmissioning pathways regulating the systemic release of immunomodulatory atoms, and direct effects by CB2R-controlled inhibition of macrophages, microglia and lymphocyte function. Strong endocannabinoid signaling could hold the key as a substitute to the use of exogenously induced cannabinoids.